anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study is a pilot cluster randomized controlled hybrid Type II effectiveness-implementation trial in 4 rural Child Advocacy Centers. All CACs will implement the Care Process Model for Pediatric Traumatic Stress (CPM-PTS), a mental health screening and referral protocol. CACs will be randomized to team-focused implementation (n = 2) or standard implementation (n = 2). The study is designed to evaluate the acceptability, appropriateness, and feasibility of team-focused implementation strategies. It will also test the effect of the CPM-PTS on caregiver understanding of mental health needs and intentions to initiate treatment. Mixed methods will be used to evaluate the feasibility of team-focused implementation, test the effect of team strategies on teamwork, and assess implementation outcomes. Administrative data collected anonymously from caregivers will be used to test the effectiveness of the CPM-PTS.
Subjects placed into this group will undergo electrical stimulation following anterior cruciate ligament reconstruction (ACLr). Subjects will be required to report 2 times per week for 6 weeks following ACLr for electrical stimulation therapy. Electrical stimulation therapy post-reconstruction will commence immediately post-ACLr and end at week 6.
The fatty acid esters have molecular weights below about 1000 dalton and the fatty acid component of the fatty acid ester is a saturated or unsaturated fatty acid having a total number of carbon atoms of from C8 to C22. Particularly suitable fatty acid esters for use according to the invention are fatty acid esters which are selected from the group consisting of fatty acid esters of polyhydric alcohols, fatty acid esters of hydroxycarboxylic acids, fatty acid esters of monosaccharides, fatty acid esters of glycerylphosphate derivatives, fatty acid esters of glycerylsulfate derivative, and mixtures thereof. Excellent bioadhesive properties have been observed for fatty acid esters of glyceryl monooleate, glyceryl monolinoleate or glyceryl monolinolenate. Methods are described for administering an active or protective substance to undamaged or damaged skin or mucosa of an animal such as a human by combining the active or protective substance with a bioadhesive fatty acid ester. The mucosa may be the oral, aural, nasal, lung, gastrointestinal, vaginal, or rectal mucosa. The administration may also be to body cavities such as the oral cavity, e.g. via buccal administration.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to clinical immunology and aims at patient-specific immunotherapy. That is ensured by the use in a nidus zone of supernatant of stimulated autologous leukocytes with the concentration of neutrophilic antimicrobial peptides in supernatant not less than 2000 pg/ml. Supernatant is administered in applications and/or subcutaneously, or submucosally, or in instillations for 5-10 days. ^ EFFECT: method provides prevention of secondary immunodeficiency, reduced inflammation, wound decontamination, stimulated repair, allows lower dosages and period of administering antibiotics, due to joint action of a complex of cytokines and antimicrobial neutrophilic peptides produced by autologous leukocytes. ^ 6 cl, 3 tbl, 4 ex
A set of baseline treatment information is received. From the set of baseline treatment information, a set of incidental information is determined. Based on the set of baseline treatment information and the set of incidental information, a treatment mitigation area is generated. Based on the set of baseline treatment information, the set of incidental information, and the treatment mitigation area, a treatment mitigation model is created. An affected individual is identified, based on the treatment mitigation model. The affected individual is notified of one or more treatment mitigation recommendations.
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to burosumab-twza in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In XLH clinical studies, none (0/13) of the 1- to 4-year-old patients, 19% (10/52) of the 5- to 12-year-old patients, and 15% (20/131) of the adult patients tested positive for anti-drug antibodies (ADA) after receiving CRYSVITA. Among these, three 5- to 12-year-old patients tested positive for neutralizing antibodies. The presence of ADA was not associated with clinically relevant changes in pharmacokinetics, pharmacodynamics, efficacy, and safety of burosumab in patients with XLH.

In one TIO clinical study, 14% (2/14) of the adult patients tested positive for ADA after receiving CRYSVITA. None of the ADA positive patients tested positive for neutralizing antibodies. In another TIO clinical study, none of the 13 adult patients tested positive for ADA after receiving CRYSVITA.
Subjects with normal renal function will be matched by age (±10 years), weight (± 20%), and gender to the pooled mean values of subjects with the moderate renal impairment. Subjects will receive 1 dose of ISIS 681257.
The present invention relates to a medicine for treating Alzheimer's disease. [Solution] When adding acid, In Alzheimer's disease, amyloid β protein, which is a collection of fragments excised by two enzymes, β-sectorase and γ-sectorase, from amyloid β-precursor protein in brain cell membranes, accumulates to forms a mass called senile plaque. Since the two enzymes β-sectorase and γ-sectorase have optimum pH, the enzyme does not work if the pH value in the brain neurons is deviated from the optimum pH value. For the purpose of changing the hydrogen ion concentration, if acid is added to the brain neurons to make it acidic, the pH in the brain neurons changes and deviated from the optimum pH value. Because the two enzymes, β-sectorase and γ-sectorase, do not work, amyloid β-protein does not accumulate and senile plaques cannot be formed. When adding a base, In Alzheimer's disease, amyloid β protein, which is a collection of fragments excised by two enzymes β-sectorase and γ-sectorase from amyloid β-precursor protein in brain cell membranes, accumulates to forms a mass called senile plaque. Since the two enzymes β-sectorase and γ-sectorase have optimum pH the enzyme does not work if the pH value in the brain neurons is deviated from the optimum pH value. For the purpose of changing the hydrogen ion concentration if base is added to the brain neurons to make it basic, the pH in the brain neurons changes and deviated from the optimum pH value. Because the two enzymes, β-sectorase and γ-sectorase, do not work, amyloid β-protein does not accumulate and senile plaques cannot be formed.
Human overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg.

No data are available to suggest that physiological maneuvers (e.g., maneuvers to change the pH of the urine) would accelerate elimination of moexipril and its metabolites. The dialyzability of moexipril is not known.

Angiotensin II could presumably serve as a specific antagonist-antidote in the setting of moexipril overdose, but angiotensin II is essentially unavailable outside of research facilities. Because the hypotensive effect of moexipril is achieved through vasodilation and effective hypovolemia, it is reasonable to treat moexipril overdose by infusion of normal saline solution. In addition, renal function and serum potassium should be monitored.
Inflammation is closely associated with many neurodegenerative disorders. Yet, whether inflammation causes, exacerbates, or responds to neurodegeneration has been challenging to define because the two processes are so closely linked. Here, we disentangle inflammation from the axon damage it causes by individually blocking cytotoxic T cell function and axon degeneration. We model inflammatory damage in mouse skin, a barrier tissue that, despite frequent inflammation, must maintain proper functioning of a dense array of axon terminals. We show that sympathetic axons modulate skin inflammation through release of norepinephrine, which suppresses activation of γδ T cells via the β2 adrenergic receptor. Strong inflammatory stimulation-modeled by application of the Toll-like receptor 7 agonist imiquimod-causes progressive γδ T cell-mediated, Sarm1-dependent loss of these immunosuppressive sympathetic axons. This removes a physiological brake on T cells, initiating a positive feedback loop of enhanced inflammation and further axon damage.
Pyroptosis is an inflammatory form of programmed cell death that plays an important role in regulating tumor progression. Reniformin A (RA) is a natural compound isolated from the medicinal herb Isodon excisoides that has been applied as folk medicine in the treatment of esophageal cancer. However, whether RA has an individual function in cancer and the molecular mechanisms remain unclear. Here, we show that in non-small-cell lung cancer (NSCLC), RA inhibits tumor growth by functioning as a pyroptosis inducer to promote TLR4/NLRP3/caspase-1/GSDMD axis. Specially, RA treatment increased Toll-like receptor 4 (TLR4) protein expression level by enhancing the TLR4 stability. Based on the molecular docking, we identified that RA directly bound to TLR4 to activate the NLRP3 inflammasome and promote pyroptosis in A549 cells. Moreover, TLR4 is essential for RA-induced pyroptosis, and loss of TLR4 abolished RA-induced pyroptosis and further reduced the inhibitory effect of RA on NSCLC. In vivo experiments confirmed that RA inhibited the growth of lung tumors in mice by affecting pyroptosis in a dose-dependent manner. Furthermore, TLR4 knockdown abolished RA-induced pyroptosis and inhibited the effect of RA chemotherapy in vivo. In conclusion, we propose that RA has a significant anticancer effect in NSCLC by inducing TLR4/NLRP3/caspase-1/GSDMD-mediated pyroptosis, which may provide a potential strategy for the treatment of NSCLC.
The invention discloses a medicine bag for treating seasonal allergic asthma. A proper amount of Huai chrysanthemum, xanthium fruits, herba houttuyniae, divaricate saposhnikovia root and mint are taken and ground for next use. A mouth mask with the shape similar to that of the common mouth mask and with an upper opening communicated with a gauze interlayer space is prepared and is filled with the medicine bag with the above drug powder. The medicine bag releases a delicate fragrance and has the effect of dredging orifices. The medicine bag is worn before contact with an allergen or in an allergy season and instantly produces effects after wearing for about 5min. One dosage of the medicine bag can be used for about 3 months. After use, the mouth mask is timely put into a plastic bag and prevents medicine smell release and medicine failure loss. The medicine bag solves the problem that the drug for treating seasonal allergic asthma has large side effect, has long taking tine and has a high recurrence rate after drug withdrawal and is suitable for treating seasonal allergic asthma.
PURPOSE:To enhance the availability of a recorder by constituting it so that data recorded in the recorder and its control variable can be designated arbitrarily from a patient monitoring device side. CONSTITUTION:Data which can be designated from a patient monitoring device side consist of three of a waveform, a character and picture drawing. The position W1 of a waveform W shows a position in which a waveform on the recording paper of a recorder is recorded, the kind W2 shows the classification of a waveform to be recorded of an electrocardiogram, blood pressure, etc., and sensitivity W3 shows a size in the vertical direction of the waveform, and thickness W4 shows the thickness of a line of the waveform. The position C1 of a character C shows a position in which a character is recorded, the kind C2 shows the classification of the character of a KANJI (Chinese character), a KANA (Japanese syllabary), a KATAKANA (square form of Japanese syllabary), the alphabet, etc., and magnification C3 shows magnification in the vertical direction and the horizontal direction of the character compared with a standard size. Also, the position P1 of picture drawing P shows a position in which picture drawing is recorded, and magnifications P2, P3 are magnifications in the vertical direction and the horizontal direction compared with original picture drawing. The position W1 of a control variable designates the upper limit and the lower limit positions of the waveform, and the kind W2 designates, for instance, the classification in an electrocardiogram. The sensitivity W3 designates as sensitivity 1, 1/2 and 2, and the thickness W4 designates the thickness of easily visible waveform.
On the evening before colonoscopy, drink 1L of 2L PEG/Asc (Haprep®) solution, additionally allow another 500 ml of water. On the day of colonoscopy, drink 1L of 2L PEG/Asc solution, additionally allow another 500 ml of water.
Blood pressure(BP) of the longevous population with hypertension and/or frailty was under-investigated. To investigate the association between age, BP, variation of BP, and survival among the old adults with different status of hypertension and frailty, the present study included adults ≥65 years in the Chinese Longitudinal Healthy Longevity Survey (2008-2018), defined frailty using the Fried criteria, and identified hypertension by self-report or SBP/DBP ≥ 140/90 mm Hg. The association between age and BP were investigated using linear regression models. Variation of BP was defined if annual change of BP lower than quartile 1(sharp decrease) or higher than quartile 3(sharp increase). The association between age and BP variation were investigated using multinominal logistic regression models. The association between BP and survival was analyzed using Cox regression models. Among 13,447 adults (centenarian: 1965[14.6%]), age was positively associated with SBP in robust hypertensive elderly but negatively associated with it in frail hypertensive elderly. Annual change of BP was more likely to be increment among the normotensive elderly, but be decrement among the hypertensive elderly, especially among those with frailty. SBP < 120 mmHg was the risk factor of mortality among the frail oldest-old (≥85 years) while SBP ≥ 150 mmHg was that among the robust young-old (65-84 years). DBP ≥ 90 mmHg was the risk factor of mortality both in the robust young-old and the frail oldest old. In conclusion, age and frailty might be the criteria to predict the change of BP to guide the BP management of the longevous population.
Objective: The transjugular or transfemoral approach is used as a common method for hepatic venous pressure gradient (HVPG) measurement in current practice. This study aims to confirm the safety and effectiveness of measuring HVPG via the forearm venous approach. Methods: Prospective recruitment was conducted for patients with cirrhosis who underwent HVPG measurement via the forearm venous approach at six hospitals in China and Japan from September 2020 to December 2020. Patients' clinical baseline information and HVPG measurement data were collected. The right median cubital vein or basilic vein approach for all enrolled patients was selected. The HVPG standard process was used to measure pressure. Research data were analyzed using SPSS 22.0 statistical software. Quantitative data were used to represent medians (interquartile ranges), while qualitative data were used to represent frequency and rates. The correlation between two sets of data was analyzed using Pearson correlation analysis. Results: A total of 43 cases were enrolled in this study. Of these, 41 (95.3%) successfully underwent HVPG measurement via the forearm venous approach. None of the patients had any serious complications. The median operation time for HVPG detection via forearm vein was 18.0 minutes (12.3~38.8 minutes). This study confirmed that HVPG was positively closely related to Child-Pugh score (r = 0.47, P = 0.002), albumin-bilirubin score (r = 0.37, P = 0.001), Lok index (r = 0.36, P = 0.02), liver stiffness (r = 0.58, P = 0.01), and spleen stiffness (r = 0.77, P = 0.01), while negatively correlated with albumin (r = -0.42, P = 0.006). Conclusion: The results of this multi-centre retrospective study suggest that HVPG measurement via the forearm venous approach is safe and feasible.
FIELD: immunology. SUBSTANCE: invention relates to transferring a bioactive compound, usually antigen, in animal body. For that, effective quantity of bioactive compound is placed into microcapsules up to 10 mcm in size made of biologically compatible indifferent material. Effective amount of these microcapsules is introduced, mainly orally, into immunized animals. According to invention, material of microcapsules is biologically active polymer or copolymer being capable of passing through gastrointestinal tract or of localizing on a mucous surface. Microcapsules do not undergo biodegradation or undergo it to an insignificant extent. The latter ensures transfer of bioactive compound onto peyer's patches or other mucous membrane-associated lymphatic tissues. Microcapsules are incorporated therein with no loss in activity and in amounts sufficient to stimulate system immunogenesis or immune response of mucous membranes. Because of pulsing release of agent, system immunity is induced and immune system of mucous membranes activated. EFFECT: enhanced effect of bioactive compound. 16 cl, 1 dwg, 19 tbl, 12 ex
This present disclosure is related to the field of 1-(substituted-benzoyl)-5-fluoro-4-imino-3-methyl-3,4-dihydropyrimidin-2(1H)-ones and their derivatives and to the use of these compounds as fungicides. Fungicides are compounds, of natural or synthetic origin, which act to protect and/or cure plants against damage caused by agriculturally relevant fungi. Generally, no single fungicide is useful in all situations. Consequently, research is ongoing to produce fungicides that may have better performance, are easier to use, and cost less. The present disclosure relates to 1-(substituted-benzoyl)-5-fluoro-4-imino-3-methyl-3,4-dihydropyrimidin-2(1 H)-one compounds and their use as fungicides. The compounds of the present disclosure may offer protection against fungi and fungi like organisms including ascomycetes, basidiomycetes, deuteromycetes, and oomycetes.
The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E40RF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or “E4 cassette”) includes E40RF3 and at least one other portion selected from E40RF4, E40RF6/7 and E40RF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.
Psychiatric adverse reactions have been reported in patients treated with modafinil. 

In the adult modafinil controlled trials, psychiatric symptoms resulting in treatment discontinuation (at a frequency ≥0.3%) and reported more often in patients treated with modafinil compared to those treated with placebo were anxiety (1%), nervousness (1%), insomnia (<1%), confusion (<1%), agitation (<1%), and depression (<1%).

Postmarketing adverse reactions associated with the use of modafinil have included mania, delusions, hallucinations, suicidal ideation, and aggression, some resulting in hospitalization. Many, but not all, patients had a prior psychiatric history. One healthy male volunteer developed ideas of reference, paranoid delusions, and auditory hallucinations in association with multiple daily 600 mg doses of modafinil (three times the recommended dose) and sleep deprivation. There was no evidence of psychosis 36 hours after drug discontinuation. 

Caution should be exercised when modafinil is given to patients with a history of psychosis, depression, or mania. Consideration should be given to the possible emergence or exacerbation of psychiatric symptoms in patients treated with modafinil. If psychiatric symptoms develop in association with modafinil administration, consider discontinuing modafinil.
Based on its mechanism of action, ENHERTU can cause fetal harm when administered to a pregnant woman. In postmarketing reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Based on its mechanism of action, the topoisomerase inhibitor component of ENHERTU, DXd, can also cause embryo-fetal harm when administered to a pregnant woman because it is genotoxic and targets actively dividing cells [see Use in Specific Populations (8.1), Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)]. Advise patients of the potential risks to a fetus.

Verify the pregnancy status of females of reproductive potential prior to the initiation of ENHERTU. Advise females of reproductive potential to use effective contraception during treatment and for 7 months after the last dose of ENHERTU. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose of ENHERTU [see Use in Specific Populations (8.1, 8.3)].
A method, system and computer program product for ensuring quality in electronic health data. Data processing pipelines among different tenants are monitored for data artifacts generated from electronic health data, where a “data artifact” refers to the tangible by-products produced during the processing of the electronic health record datasets generated by the electronic health record systems as well as the datasets themselves. Out of the generated data artifacts, those data artifacts that are produced from the same stage of the data processing pipelines among the different tenants are aggregated. A set of metrics at various levels of a dataset hierarchy are produced from the aggregated data artifacts. Such metrics provide information about a quality of the electronic health data. A quality report, which may include flagged issues with the datasets, is then generated and presented to a user based on an analysis of the produced set of metrics.
PROBLEM TO BE SOLVED: To improve the stabilities of caffeines and a composition (e.g. an aqueous liquid preparation) containing the caffeines. SOLUTION: An aminoalkanesulfonic acid (e.g. taurine) or a derivative thereof is formulated with a compound (caffeines) represented by formula (1) (wherein, R1, R2 and R3 are each hydrogen atom or an alkyl group) or a salt thereof to prevent the deactivation or precipitation of the caffeines or the salt thereof and to stabilize an aqueous composition. The aqueous composition is useful as a composition to be applied to a mucous membrane, e.g. an aqueous preparation (e.g. a nasal drop, an eye lotion or an eye wash) to be applied to ocular- mucous membrane or nasal mucous membrane.